Entero Therapeutics (GRDX) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Key Stats

• Today's Range: $5.59 to $6.45
• 50-Day Range: $2.01 to $6.80
• 52-Week Range: $1.08 to $6.93
• Volume: 121,198 shs
• Average Volume: 169,171 shs
• Market Capitalization: $42.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Entero Therapeutics Stock Analysis - MarketRank™

Entero Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 73rd out of 87 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Entero Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Entero Therapeutics has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.74% of the float of Entero Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entero Therapeutics has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entero Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entero Therapeutics does not currently pay a dividend.

Dividend Growth

Entero Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for GRDX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.75% of the stock of Entero Therapeutics is held by insiders.

Percentage Held by Institutions

12.30% of the stock of Entero Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/27/2026
• Today: 6/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GRDX
• CIK: 1604191
• Web: N/A
• Phone: (561) 589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.39 million
• Net Margins: N/A
• Pretax Margin: -12,697.47%
• Return on Equity: -49.81%
• Return on Assets: -11.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.16
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 1,055.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.42 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 6,650,000
• Free Float: 6,603,000
• Market Cap: $42.23 million
• Optionable: N/A
• Beta: 1.80